Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA(R) (lumateperone) for the Treatment of Bipolar Depression

Source :: GlobeNewswire. February 22, 2021
Publication Year :: 2021
Abstract: NEW YORK, Feb 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- If approved, CAPLYTA has the potential to treat the broadest range of patients with bipolar depression. Intra-Cellular Therapies, Inc. [...]

Subjects :: United States. Food and Drug Administration
Bipolar disorder -- Drug therapy
Homeopathy -- Materia medica and therapeutics
Biotechnology industry
Therapeutics
Drug approval
Banking, finance and accounting industries
Business
Caplyta (Medication)

Tools